Evofem Biosciences Management
Management criteria checks 3/4
Evofem Biosciences' CEO is Saundra Pelletier, appointed in Jan 2018, has a tenure of 6.33 years. total yearly compensation is $1.52M, comprised of 36.9% salary and 63.1% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth $20.64. The average tenure of the management team and the board of directors is 3.1 years and 6.3 years respectively.
Key information
Saundra Pelletier
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 36.9% |
| CEO tenure | 6.3yrs |
| CEO ownership | 0.003% |
| Management average tenure | 3.1yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Evofem partners with a360 Media to support Phexxi prescription growth
Jul 21Evofem announces peer-reviewed publication on birth control method
Jul 12Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier
Jul 06Evofem announces U.S. patent win for birth control method
Jun 30Evofem: ACA Coverage Of Phexxi Is A Game Changer
Jan 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$560k | US$50m |
| Sep 30 2023 | n/a | n/a | US$44m |
| Jun 30 2023 | n/a | n/a | US$67m |
| Mar 31 2023 | n/a | n/a | -US$48m |
| Dec 31 2022 | US$1m | US$812k | -US$78m |
| Sep 30 2022 | n/a | n/a | -US$119m |
| Jun 30 2022 | n/a | n/a | -US$283m |
| Mar 31 2022 | n/a | n/a | -US$192m |
| Dec 31 2021 | US$3m | US$812k | -US$206m |
| Sep 30 2021 | n/a | n/a | -US$194m |
| Jun 30 2021 | n/a | n/a | -US$150m |
| Mar 31 2021 | n/a | n/a | -US$169m |
| Dec 31 2020 | US$4m | US$781k | -US$142m |
| Sep 30 2020 | n/a | n/a | -US$114m |
| Jun 30 2020 | n/a | n/a | -US$98m |
| Mar 31 2020 | n/a | n/a | -US$81m |
| Dec 31 2019 | US$3m | US$847k | -US$80m |
| Sep 30 2019 | n/a | n/a | -US$82m |
| Jun 30 2019 | n/a | n/a | -US$87m |
| Mar 31 2019 | n/a | n/a | -US$75m |
| Dec 31 2018 | US$8m | US$738k | -US$126m |
| Sep 30 2018 | n/a | n/a | -US$131m |
| Jun 30 2018 | n/a | n/a | -US$188m |
| Mar 31 2018 | n/a | n/a | -US$172m |
| Dec 31 2017 | US$2m | US$731k | -US$109m |
Compensation vs Market: Saundra's total compensation ($USD1.52M) is above average for companies of similar size in the US market ($USD674.55K).
Compensation vs Earnings: Saundra's compensation has been consistent with company performance over the past year.
CEO
Saundra Pelletier (53 yo)
6.3yrs
Tenure
US$1,520,455
Compensation
Ms. Saundra Pelletier has been Chief Executive Officer and President of Evofem Biosciences, Inc. since January 17, 2018. Ms. Pelletier has been an Executive Director of Evofem Biosciences, Inc. since Janua...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim Chair | 6.3yrs | US$1.52m | 0.0026% $ 20.6 | |
| CFO & Secretary | 1.1yrs | US$438.85k | 0% $ 0 | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| Vice President of Sales | 3.1yrs | no data | no data | |
| Head of Human Resources | no data | no data | no data | |
| Chief of Staff | no data | no data | no data |
3.1yrs
Average Tenure
Experienced Management: EVFM's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim Chair | 6.3yrs | US$1.52m | 0.0026% $ 20.6 | |
| Independent Director | 6.3yrs | US$70.00k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$55.00k | 0.000010% $ 0.08 | |
| Independent Director | 6.3yrs | US$77.62k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$75.00k | 0.000010% $ 0.08 |
6.3yrs
Average Tenure
60yo
Average Age
Experienced Board: EVFM's board of directors are considered experienced (6.3 years average tenure).